Abstract
Safety concerns persist for long-term pediatric fluoroquinolone use. Seventy children (median age, 2.1 years) treated with levofloxacin 10-20 mg/kg once daily for multidrug-resistant tuberculosis (median observation time, 11.8 months) had few musculoskeletal events, no levofloxacin-attributed serious adverse events, and no Fridericia-corrected QT interval >450 ms. Long-term levofloxacin was safe and well tolerated.
Publication types
-
Observational Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adolescent
-
Antitubercular Agents / adverse effects
-
Antitubercular Agents / therapeutic use*
-
Child
-
Child, Preschool
-
Female
-
Heart / drug effects*
-
Humans
-
Levofloxacin / adverse effects
-
Levofloxacin / therapeutic use*
-
Male
-
Prospective Studies
-
South Africa
-
Time Factors
-
Tuberculosis, Multidrug-Resistant / drug therapy*
Substances
-
Antitubercular Agents
-
Levofloxacin